StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

BioCryst Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BioCryst Pharmaceuticals's price to sales ratio was 2.1× on Nov 11, 2026, against 2.5× a year earlier. Over the last 5 years it ranged from 2.1× to 24.4×, with a median of 4.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.1×−0.7
2025Dec 31, 20252.7×−1.0
2024Dec 31, 20243.8×+0.2
2023Dec 29, 20233.6×−5.4
2022Dec 30, 20229.0×−12.9
2021Dec 31, 202121.8×−2.7
2020Dec 31, 202024.6×−7.6
2019Dec 31, 201932.2×−8.4
2018Dec 31, 201840.6×+24.6
2017Dec 29, 201716.0×−5.3
2016Dec 30, 201621.2×+5.8
2015Dec 31, 201515.4×−31.2
2014Dec 31, 201446.7×+5.3
2013Dec 31, 201341.3×+38.7
2012Dec 31, 20122.6×+2.6
2011Dec 30, 20110.0×–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?